The 3 cases of cervical cancer associated with pregnancy / 대한산부인과학회지

The invasive cervical cancer associated with pregnancy is rare case, but the most common cancer among the malignancy associated with pregnancy. The diagnosis and the symptoms are not different from the non-pregnancy case, but vaginal bleeding which is the main symptom of cervical cancer is often misconceived for usual complication of pregnancy, and could delay the diagnosis. Pregnancy provides ideal times for cervical cancer screening, since pelvic examination could be easily performed. So all pregnant patients should have a cytology at the initial antenatal visit. The treatment is not significantly different from the non-pregnancy, but when we determine the treatment plan, the start time of treatment is most important point and it was affected by the gestational age at diagnosis and strong desire of the patients. We report 3 cases of invasive cervical cancer associated with pregnancy since 1998, and we delayed the treatment until postpartum in 2 cases.

Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix / 대한산부인과학회지

OBJECTIVE: This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma. METHODS: Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004. RESULTS: A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy. CONCLUSION: The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.